放射性标记的MMP激活炭疽蛋白用于肿瘤成像
本研究将炭疽致死毒素的保护抗原(PA)改造成仅被基质金属蛋白酶(MMP)切割后才形成膜孔(PA-L1),并用111In标记致死因子(LF)突变体,通过SPECT/CT在肿瘤异种移植模型中无创成像MMP活性。结果显示111In-LFE687A经PA-L1递送后选择性蓄积于MMP阳性MDA-MB-231肿瘤(5.98±0.62 %ID/g),而经PA-WT或不可切割PA-U7递送则较低。结论提示放射性标记的突变炭疽致死毒素有望用于肿瘤MMP活性无创成像。
要点
- PA-L1体外激活与炭疽受体表达及MMP活性相关(HT1080>MDA-MB-231>B8484>MCF7)。
- 111In-LFE687A经PA-L1递送后选择性蓄积于MMP阳性MDA-MB-231肿瘤。
- 广谱MMP抑制剂GM6001可阻断PA-L1介导的递送。
核心结论
- 放射性标记的突变炭疽致死毒素有望用于肿瘤组织MMP活性的无创成像。
研究设计与样本
- 研究在HT1080、MDA-MB-231、B8484和MCF7癌细胞中评估MMP介导的PA-L1激活与炭疽受体表达及MMP活性的相关性。
- 使用SPECT/CT在体内测量111In标记的PA-L1、PA-WTK563C或LFE687A在肿瘤和正常组织中的摄取。
主要发现
- PA-L1在体外激活与炭疽受体表达和MMP活性相关,顺序为HT1080>MDA-MB-231>B8484>MCF7。
- PA-L1介导的111In-LFE687A递送经共聚焦显微镜用荧光标记LFE687A证实,并被广谱MMP抑制剂GM6001阻断。
- 静脉给药3小时后,111In-PA-L1在MDA-MB-231肿瘤异种移植中选择性蓄积为5.7±0.9 %ID/g。
- 111In-LFE687A经MMP可激活的PA-L1选择性递送至MMP阳性MDA-MB-231肿瘤组织为5.98±0.62 %ID/g,而经弗林蛋白酶可切割的PA-WT为1.05±0.21 %ID/g,经不可切割PA变体对照PA-U7为2.74±0.24 %ID/g。
临床怎么用
- 该策略可能为肿瘤MMP活性提供无创SPECT成像方法,但尚未进入临床常规应用。
局限性
- 研究仅基于细胞和肿瘤异种移植模型,未报告人体数据或临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Increased activity of matrix metalloproteinases (MMPs) is associated with worse prognosis in different cancer types. The wild-type protective antigen (PA-WT) of the binary anthrax lethal toxin was modified to form a pore in cell membranes only when cleaved by MMPs (to form PA-L1). Anthrax lethal factor (LF) is then able to translocate through these pores. Here, we used a 111In-radiolabeled form of LF with the PA/LF system for noninvasive in vivo imaging of MMP activity in tumor tissue by SPECT. Methods: MMP-mediated activation of PA-L1 was correlated to anthrax receptor expression and MMP activity in a panel of cancer cells (HT1080, MDA-MB-231, B8484, and MCF7). Uptake of 111In-radiolabeled PA-L1, 111In-PA-WTK563C, or 111In-LFE687A (a catalytically inactive LF mutant) in tumor and normal tissues was measured using SPECT/CT imaging in vivo. Results: Activation of PA-L1 in vitro correlated with anthrax receptor expression and MMP activity (HT1080 > MDA-MB-231 > B8484 > MCF7). PA-L1-mediated delivery of 111In-LFE687A was demonstrated and was corroborated using confocal microscopy with fluorescently labeled LFE687A Uptake was blocked by the broad-spectrum MMP inhibitor GM6001. In vivo imaging showed selective accumulation of 111In-PA-L1 in MDA-MB-231 tumor xenografts (5.7 ± 0.9 percentage injected dose [%ID]/g) at 3 h after intravenous administration. 111In-LFE687A was selectively delivered to MMP-positive MDA-MB-231 tumor tissue by MMP-activatable PA-L1 (5.98 ± 0.62 %ID/g) but not by furin-cleavable PA-WT (1.05 ± 0.21 %ID/g) or a noncleavable PA variant control, PA-U7 (2.74 ± 0.24 %ID/g). Conclusion: Taken together, our results indicate that radiolabeled forms of mutated anthrax lethal toxin hold promise for noninvasive imaging of MMP activity in tumor tissue.
引用
- Elvina Xavier MA, Liu S, Bugge TH, et al. Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins. J Nucl Med. 2019. PMID: 30954944. doi:10.2967/jnumed.119.226423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。